NASDAQ:SELBSelecta Biosciences Stock Price, Forecast & News

$3.63

-0.16 (-4.22 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$3.60

Now: $3.63▼

$3.93

50-Day Range

$2.51

MA: $3.19▼

$3.98

52-Week Range

$1.28

Now: $3.63▼

$4.83

Volume1.03 million shs

Average Volume718,540 shs

Market Capitalization$317.59 million

P/E RatioN/A

Dividend YieldN/A

Beta1.43

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout. It is also developing SEL-403, which is in Phase I clinical trials for the treatment of patients with malignant pleural or peritoneal mesothelioma. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., and BIND Therapeutics, Inc.; and a strategic partnership with Asklepios BioPharmaceutical, Inc. for the development, manufacture, and commercialization of targeted therapeutics for adeno-associated virus gene therapies in the areas of high medical need. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.

Beat the Market (BTM) Rank^™

4.5 Analyst's Opinion

Consensus Rating
Selecta Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.80, Selecta Biosciences has a potential upside of 87.3% from its current price of $3.63.
Amount of Analyst Coverage
Selecta Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.1 Community Rank

Outperform Votes
Selecta Biosciences has received 281 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Selecta Biosciences has received 373 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Selecta Biosciences has received 57.03% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote “Outperform” if you believe SELB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Selecta Biosciences does not currently pay a dividend.
Dividend Growth
Selecta Biosciences does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Selecta Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 22.40% of the stock of Selecta Biosciences is held by insiders.
Percentage Held by Institutions
64.59% of the stock of Selecta Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Selecta Biosciences are expected to grow in the coming year, from ($0.81) to ($0.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Selecta Biosciences is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Selecta Biosciences is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Selecta Biosciences has a P/B Ratio of 36.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.25 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SELB

Previous Symbol

CUSIPN/A

CIK1453687

Webselectabio.com

Phone617-923-1400

Debt

Debt-to-Equity RatioN/A

Current Ratio2.48

Quick Ratio2.48

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$6.68 million

Price / Sales47.54

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.10 per share

Price / Book36.30

Profitability

EPS (Most Recent Fiscal Year)($1.22)

Net Income$-55,350,000.00

Net MarginsN/A

Return on Equity-1,206.08%

Return on Assets-91.53%

Miscellaneous

Employees39

Outstanding Shares87,490,000

Market Cap$317.59 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive SELB News and Ratings via Email

Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter.

Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions

How has Selecta Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SELB stock has increased by 17.5% and is now trading at $3.63. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Selecta Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Selecta Biosciences.

When is Selecta Biosciences' next earnings date?

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Selecta Biosciences.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences Inc (NASDAQ:SELB) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.07. View Selecta Biosciences' earnings history.

What price target have analysts set for SELB?

7 analysts have issued 1 year target prices for Selecta Biosciences' stock. Their forecasts range from $4.00 to $10.00. On average, they expect Selecta Biosciences' stock price to reach $6.80 in the next year. This suggests a possible upside of 87.3% from the stock's current price. View analysts' price targets for Selecta Biosciences.

Has Selecta Biosciences been receiving favorable news coverage?

Media coverage about SELB stock has trended positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Selecta Biosciences earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutSelecta Biosciences.

Who are some of Selecta Biosciences' key competitors?

Some companies that are related to Selecta Biosciences include Karyopharm Therapeutics (KPTI), Tricida (TCDA), Arvinas (ARVN), Kiniksa Pharmaceuticals (KNSA), Phathom Pharmaceuticals (PHAT), Supernus Pharmaceuticals (SUPN), Revance Therapeutics (RVNC), Odonate Therapeutics (ODT), Esperion Therapeutics (ESPR), Cytokinetics (CYTK), Aimmune Therapeutics (AIMT), I-Mab (ARQT), Phibro Animal Health (PAHC), Passage Bio (ORIC) and Enanta Pharmaceuticals (ENTA). View all competitors.

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Novavax (NVAX), Viking Therapeutics (VKTX), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Catalyst Pharmaceuticals (CPRX), Agile Therapeutics (AGRX) and Amarin (AMRN).

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the following people:

Dr. Carsten Brunn, CEO, Pres & Director (Age 49, Pay $942.52k)
Ms. Elona Kogan J.D., Esq., Gen. Counsel & Corp. Sec. (Age 51, Pay $480.77k)
Mr. Stephen Smolinski, Chief Commercial Officer (Age 55, Pay $549.39k)
Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D., Co-Founder and Co-Chair of the Scientific Advisory Board
Mr. Bradford D. Dahms, CFO, Principal Financial Officer & Principal Accounting Officer (Age 32)

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Vivo Capital LLC (8.97%), Wasatch Advisors Inc. (3.68%), Orbimed Advisors LLC (2.96%), Ghost Tree Capital LLC (1.97%), RA Capital Management L.P. (1.00%) and BlackRock Inc. (0.79%). Company insiders that own Selecta Biosciences stock include Amir Nashat, Carsten Brunn and Timothy C Barabe. View institutional ownership trends for Selecta Biosciences.

Which major investors are selling Selecta Biosciences stock?

SELB stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., and Orbimed Advisors LLC. View insider buying and selling activity for Selecta Biosciences.

Which major investors are buying Selecta Biosciences stock?

SELB stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, RA Capital Management L.P., Ghost Tree Capital LLC, Driehaus Capital Management LLC, Citigroup Inc., Two Sigma Investments LP, Jane Street Group LLC, and Squarepoint Ops LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, and Timothy C Barabe. View insider buying and selling activity for Selecta Biosciences.

How do I buy shares of Selecta Biosciences?

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $3.63.

How big of a company is Selecta Biosciences?

Selecta Biosciences has a market capitalization of $317.59 million and generates $6.68 million in revenue each year. The company earns $-55,350,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Selecta Biosciences employs 39 workers across the globe.

What is Selecta Biosciences' official website?

The official website for Selecta Biosciences is selectabio.com.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff